Please note that additional things may come up during the course of screening that impact enrollment eligibility, which is ultimately up to the discretion of the study team.
You may be eligible for this research study if you:
- Are between the ages of 60 and 89
- Have a reliable study partner who has frequent (i.e., at least twice per month) contact with the subject and is able to provide information about functional abilities
- Are in range on the brief cognitive screening exam
- Have no informant report of significant cognitive decline in prior year
- Have no evidence from the screening visit suggesting a neurodegenerative disorder
- Are willing to complete both baseline and 24-month follow-up procedures
You may not be eligible if you have the following:
- Major psychiatric disorder (e.g., schizophrenia, bipolar disorder, untreated major depression within past year)**
- Neurological conditions affecting cognition (e.g., Parkinson’s disease, Mild Cognitive Impairment)
- Immune conditions and other conditions affecting cognition (e.g., lupus, respiratory failure)
- Systemic illnesses (e.g., current cancer, renal failure, respiratory failure)
- Substance abuse/dependence (DSM-V criteria)
- Current medication use likely to affect the nervous system and cognition (e.g., long-acting benzodiazepines; neuroleptics in the phenothiazine and haloperidol families)
- Current medication use that precludes lumbar punctures (e.g., anticoagulants, antiplatelets, heparin shots, or some other types of blood thinner medications: Warfarin [coumadin], Pradaxa [dabigatran], Xarelto [rivaroxaban], Eliquis [apixaban), or Plavix [clopidogrel]).
- Significant sensory or motor deficits that would interfere with cognitive testing
- Factors that preclude MR imaging (e.g., pacemaker)
- Factors that preclude lumbar punctures (e.g., lower back surgery)
**Prospective participants who previously received a diagnosis of major depression in the past 2 years, but are actively being treated with an anti-depressant and are not reporting significant mood symptoms at study entry may still be considered for enrollment.